Q4FY20 revenues declined 12.7% YoY to | 3845.7 crore (I-direct estimate: | 3715 crore) mainly due to Kyowa divestment and due to 9.3% YoY decline in US revenues to | 1579.1 crore (I-direct estimate: | 1483 crore). Domestic formulations grew 13.3% YoY to | 1192.1 crore (I-direct estimate: | 1137 crore). EBITDA margins contracted 614 bps YoY to 13.7% (I-direct estimate: 13.2%) due to lower gross margins and higher employee cost. EBITDA de-grew 39.8% YoY to | 526.3 crore (I-direct estimate: | 489 crore). Exceptional items include profit on Kyowa Pharma divestment of |...